What is XORTX Therapeutics Inc (XRTX) stock price today?

XORTX Therapeutics Inc (XRTX) currently trades at $2.86 per share. The stock has a market capitalization of $4.22M and a P/E ratio of —x.

Is XRTX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, XORTX Therapeutics Inc has a Smart Value Score of 19/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is -7.70.

Is XORTX Therapeutics Inc financially healthy?

XORTX Therapeutics Inc's Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of -7.70 places it in the distress.

XRTX

XORTX Therapeutics Inc

NASDAQ: XRTX · HEALTHCARE · BIOTECHNOLOGY

$2.86

+4.76% today

Updated 2026-04-30

Market cap

$4.22M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.80

Dividend yield

—

52W range

$2 – $7

Volume

1.5M

Market cap

$4.22M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.80

Dividend yield

—

52W range

$2 – $7

Volume

1.5M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

3.7

Growth

4.5

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-7.7

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$14.04

+390.91%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.03x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -7.70 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-1.00M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-6.99M	$-2.86M	$-4.54M	$-3.71M	$-823315.00
EPS	—	—	—	—	$-2.80
Free cash flow	$-9.01M	$-6.63M	$-5.04M	$-3.87M	$-1.00M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
XRTX	$4.22M	19	3.7	3.0	5.0	4.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

XORTX Therapeutics Inc trades at $2.86. Our Smart Value Score of 19/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -7.70, it sits in the distress.

Frequently asked questions

What is XORTX Therapeutics Inc's stock price?

XORTX Therapeutics Inc (XRTX) trades at $2.86.

Is XORTX Therapeutics Inc overvalued?

Smart Value Score 19/100 (Grade F, Strong Sell).

What is the price target of XORTX Therapeutics Inc (XRTX)?

The analyst target price is $14.04, representing +390.9% upside from the current price of $2.86.

Piotroski F-Score?

1/9 — weak financial health.

Altman Z-Score?

-7.70 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.xortx.com

Quick metrics

P/S ratio—

ROE-98.00%

Beta0.09

50D MA$2.22

200D MA$3.16

Shares out0.00B

Float0.00B

Short ratio—

Avg volume1.5M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

XRTX vs LLY →XRTX vs JNJ →XRTX vs ABBV →Stock screener →